This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Stephanie Gallagher, PharmD, MBA Senior Clinical Product Marketing Manager, Omnicell The sterile compounding industry has been under great scrutiny due to alarming frequency and severity of adverse events from IV compounding, such as the New England Compounding Center catastrophe in 2012.
Lisa Armburger Director, Client Success Executive, Omnicell 340B The pressures of the last year have underscored the importance of the 340B program and its impact on hospital finances. Download our recent eBook to access the tools you need to build a business case around the value of a dedicated 340B program manager.
Not only was the organization the first to sue the government, but it has also provided a great public service by developing a helpful tracking tool that you can download and other resources on the ongoing contract pharmacy battle.
Madeline Wallack, a co-author of the OIG reports and co-founder of consulting firm Rx|X, points out that the database is underutilized since the pricing files are not downloadable. As a result, it is difficult for her clients to conduct widescale price comparisons against wholesaler files.
Madeline Wallack, a co-author of the OIG reports and co-founder of consulting firm Rx|X, points out that the database is underutilized since the pricing files are not downloadable. As a result, it is difficult for her clients to conduct widescale price comparisons against wholesaler files.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content